References in periodicals archive ?
Kimberly Smith, M.D., Head of Research & Development at ViiV Healthcare, said: 'We are excited to report that for the first time since the AIDS epidemic started more than 30 years ago, our ATLAS-2M study has demonstrated that it is possible to maintain suppression of the HIV virus with an injectable regimen containing two drugs administered every two months.
Cabotegravir is being developed by ViiV Healthcare for the treatment and prevention of HIV.
ViiV Healthcare, majority owned by GlaxoSmithKline plc (NYSE:GSK), with Pfizer Inc.
ViiV Healthcare is a specialist HIV company majority owned by GSK, with Pfizer Inc and Shionogi Ltd as shareholders.
The ATLAS and FLAIR studies are part of ViiV Healthcare's innovative clinical trial programme for 2-drug regimens (2DRs).
Kimberly Smith, MD, Head of Global Research & Medical Strategy at ViiV Healthcare, said, 'With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important consideration for the community.
Max joined ViiV Healthcare in February of 2016, where he currently serves as vice president and head of clinical development, and is accountable for the development of early and late development assets such as the HIV-1 Attachment Inhibitor and the ViiV Healthcare early development pipeline.
ViiV said Juluca is the first two-drug regimen comprising dolutegravir 50 mg, an integrase strand transfer inhibitor, and rilpivirine 25 mg, a non-nucleoside reverse transcriptase inhibitor from Janssen Therapeutics.
However, we also see medium-term pressure building on the financial risk profile as visibility on the operating performance becomes more limited after 2017 and considering potential payouts related to the buy-out of minority shareholders in its ViiV and Consumer Health operations.
UK-based drugmaker GlaxoSmithKline plc's (LSE: GSK) majority owned ViiV Healthcare specialist HIV company has completed two transactions with Bristol-Myers Squibb to acquire the US drugmaker's late-stage HIV R/D assets and its portfolio of preclinical and discovery stage HIV research assets, GSK said.
Sir Andrew also noted the strong performance of Glaxo's HIV drugs arm, ViiV Healthcare - which saw sales increase by 15%.
[ClickPress, Tue Jan 28 2014] Global Market Direct's pharmaceuticals report, "ViiV Healthcare Limited - Product Pipeline Review - 2013" provides data on the ViiV Healthcare Limited's research and development focus.
Acronyms browser ?
Full browser ?
- Viidumae Preserve
- Viidumäe Preserve
- Viira, August
- Viira, August Peeterovich
- Viisage Technology Inc.
- Vijay Iyer
- Vijay Shanthi Builders Limited
- Vijay Shanthi Builders Ltd.
- Vijay Tanks & Vessels, Ltd.
- Vijaya Bank
- Vijaya Development Resource Center
- Vijaya Paul Cricket Academy
- Vijayanagara Empire
- Vijayanand Roadlines Ltd
- Vijayawada Municipal Corporation
- Vijayawada Thermal Power Station
- Vijayawada, India
- Vijayawada, India
- Vijece Kongresa Bosnjackih Intelektualaca
- Vijece Srpske Nacionalne Manjine